11日，沪指盘中震荡上扬，深证成指、创业板指强势拉升。截至收盘，沪指涨0.34%报3647.55点，深证 成指涨1.46%报11291.43点，创业板指涨1.96%报2379.82点，北证50指数涨1.18%，沪深北三市合计成交 18501亿元，较此前一日增加1135亿元。行业方面，医药、地产、家电、汽车、半导体、券商、酿酒等 板块走强，PEEK材料、锂矿、AI产业链股爆发，消费电子、飞行汽车概念等活跃。 东莞证券表示，当前A股市场内流动性相对充裕，交投情绪仍处于高位，整体运行状态较为健康，短期 震荡或为后续行情积蓄动能。考虑到当前市场呈现一定程度的结构分化，前期热门板块已处于相对高 位，板块轮动节奏或进一步加快，把握结构性机会将成为关键。 今日投资机会解析 锂价有望大幅上涨 宁德时代8月11日在投资者互动平台表示，公司在宜春项目采矿许可证8月9日到期后已暂停了开采作 业，正按相关规定尽快办理采矿证延续申请，待获得批复后将尽早恢复生产，该事项对公司整体经营影 响不大。 据宜春自然资源局，宁德时代该锂矿年采矿产能为3300万吨，配套建设的锂盐冶炼厂年产能为10万吨碳 酸锂，停产一个月将影响约8300吨碳酸锂产量 ...

8月11日， 发布公告，控股子公司上海复星医药产业发展有限公司(「复星医药产业」)与Expedition Therapeutics, Inc.("Expedition")签订《许可协议》，将向 Expedition授予小分子口服二肽基肽酶1(DPP-1)抑制剂XH-S004在全球(不包括中国境内及港澳地区)范围的开发、生产及商业化权利。复星医药产业将保留 XH-S004在中国境内及港澳地区的开发、生产及商业化权利。 受到上述利好消息刺激，8月12日，复星医药港股大幅高开，现涨7.55%，股价报20.8港元。 | 最高 | | | | | 20.800 | | 開市 | | | | | 20.800 | 成交量 | | | | 87.35萬 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 最低 | | | | | 20.800 | | 前收 | | | | ...

格隆汇8月12日｜复星医药(600196)H股高开7.55%报20.8港元，创2023年5月以来新高；A股高开5.52% 报28.28元。 XH-S004为复星医药拥有自主知识产权的小分子口服DPP-1抑制剂，其通过抑制DPP-1及其激活的中性 粒细胞丝氨酸蛋白酶降低炎症反应，从而阻断感染恶性循环及由此导致的气道结构损伤。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 消息面上，8月11日，复星医药宣布其控股子公司复星医药产业与Expedition签订许可协议，授予后者在 除中国境内及港澳地区以外地区开发、生产及商业化XH-S004的权利。 根据约定，Expedition将就本次合作向复星医药产业支付至多1.2亿美元不可退还的首付款、开发及监管 里程碑付款，此外，基于许可产品于许可区域的年度净销售额达成情况，由Expedition向复星医药产业 依约支付至多5.25亿美元 ...

Market Overview - The overnight performance of US stock indices showed a decline, with the Chinese concept index down by 0.29% [1] - Hong Kong's three major indices opened lower, with the Hang Seng Index down by 0.33%, the National Enterprises Index down by 0.34%, and the Hang Seng Technology Index down by 0.59% [1] Sector Performance - Large technology stocks collectively fell, with Baidu down nearly 2%, Alibaba down 1.43%, and other major players like Meituan, Tencent, and Xiaomi also experiencing declines, while JD.com managed to stay slightly positive [1] - Innovative drug concept stocks saw a rise, highlighted by Fosun Pharma securing a $645 million order, leading to a 7.55% increase in its stock price. Other pharmaceutical companies like Lijun Pharmaceutical, Yunding Xinyao, WuXi AppTec, and China Resources Pharmaceutical also experienced gains [1] - Lithium battery concept stocks continued their upward trend, with Tianqi Lithium Industries rising over 2% and Ganfeng Lithium up by 0.59% [1] - Sectors such as duty-free, automotive, Chinese brokerage firms, steel, and oil & gas equipment stocks generally declined, with China Duty Free Group down nearly 1% [1]

格隆汇8月12日｜复星医药H股高开7.55%报20.8港元，创2023年5月以来新高；A股高开5.52%报28.28元。 消息面上，8月11日，复星医药宣布其控股子公司复星医药产业与Expedition签订许可协议，授予后者在除中国境内及港澳地区以外地区开发、生产及商业 化XH-S004的权利。 XH-S004为复星医药拥有自主知识产权的小分子口服DPP-1抑制剂，其通过抑制DPP-1及其激活的中性粒细胞丝氨酸蛋白酶降低炎症反应，从而阻断感染 恶性循环及由此导致的气道结构损伤。 根据约定，Expedition将就本次合作向复星医药产业支付至多1.2亿美元不可退还的首付款、开发及监管里程碑付款，此外，基于许可产品于许可区域的年 度净销售额达成情况，由Expedition向复星医药产业依约支付至多5.25亿美元的销售里程碑款项。同时，Expedition应根据许可产品于许可区域内的年度净 销售额、按约定百分比和期限向复星医药产业支付特许权使用费。 ...

每经AI快讯，8月12日，截至发稿，复星医药(02196.HK)涨7.55%、晶泰控股(02228.HK)涨3.22%、丽珠 医药(01513.HK)涨2.35%、科伦博泰生物-B(06990.HK)涨1.14%。 ...

Core Viewpoint - Fosun Pharma's stock opened over 7% higher, reflecting positive market sentiment following the licensing agreement with Expedition Therapeutics for the development of DPP-1 inhibitor XH-S004 outside of China and Hong Kong [1] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., signed a licensing agreement with Expedition Therapeutics for the global development, production, and commercialization rights of DPP-1 inhibitor XH-S004, excluding China and Hong Kong [1] - Under the agreement, Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments based on development progress, with potential sales milestone payments of up to $525 million based on annual net sales in the licensed regions [1] Group 2: Clinical Trial Status - XH-S004 is currently in Phase II clinical trials for the treatment of non-cystic fibrosis bronchiectasis in China and in Phase Ib clinical trials for chronic obstructive pulmonary disease (COPD) [1]

Industry News - Hangzhou Municipal Justice Bureau is soliciting opinions on the draft regulations to promote the development of embodied intelligent robotics industry, emphasizing collaboration between enterprises, research institutions, and industry application units [4] - Chongqing Energy Bureau and the Central China Regulatory Bureau of the National Energy Administration issued implementation rules for distributed photovoltaic power generation, requiring a minimum self-consumption ratio of 20% for projects in urban areas and 40% for other areas [4] - India Airlines announced the suspension of flights between Delhi and Washington due to operational reasons starting September 1, 2025 [4] Company News - China Rare Earth Group stated that it has never cooperated or negotiated with any institutions regarding the so-called "Rare Earth Renminbi Stablecoin" [7] - Changan Automobile announced that all current directors and executives plan to increase their shareholdings, with each individual committing to invest no less than 300,000 RMB, totaling at least 5.7 million RMB [7] - Tian Shun Co. announced that it did not participate in the New Tibet Railway project [7] - Chengdu Huami announced the successful launch of ultra-low power RISC-V MCU [7] - Luxshare Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange [7] - Beijing University Pharmaceutical announced the termination of its business cooperation with Peking University International Hospital, facing risks of a complete halt in its main business [7] - Changchun High-tech announced that its subsidiary's clinical trial application for Camycin has been approved, with no similar products currently on the market [7] - Shanghai Jian Ke announced that its director Chen Wei is under investigation for serious violations of discipline and law [7] - Fosun Pharma announced the granting of rights to develop, produce, and commercialize the in-development product XH-S004, potentially receiving up to 645 million USD in milestone payments [7] - Wahaha Group responded to reports of cutting off distributors with annual sales below 3 million, stating that the changes in its distributor system are based on market strategy and cooperation willingness, and are part of normal dynamic optimization [7]

证券代码：600196 股票简称：复星医药 编号：临 2025-126 上海复星医药（集团）股份有限公司 关于控股子公司签署许可协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●协议类型：开发、生产及商业化许可 ●协议内容：控股子公司复星医药产业授予 Expedition 于许可区域（即除中国 境内及港澳地区外的全球范围）及领域（即人类、动物疾病的诊断和治疗）开发、 生产及商业化在研产品 XH-S004 的权利。 ●特别风险提示： 管机构（包括但不限于美国 FDA、欧洲 EMA、日本 PMDA）的批准。根据国内外新药 研发经验，新药研发是项长期工作，需要经过临床试验、注册等诸多环节，具有不 确定性。因此，许可产品于许可区域相关临床试验能否完成以及能否获得上市批准， 存在不确定性。 上市进程等作为触发条件。因此，复星医药产业实际收取的开发及监管里程碑款项， 须根据相应条件及/或时间节点的达成和约定执行，存在不确定性。 成情况作为触发条件。许可产品上市后的销售情况可能受到（包括但不限于）用药 需求、市场竞 ...

8月11日，上海复星医药（集团）股份有限公司（以下简称"复星医药"）宣布，控股子公司上海复星医 药产业发展有限公司与ExpeditionTherapeutics，Inc.（以下简称"Expedition"）签订了《许可协议》，将 向Expedition授予小分子口服二肽基肽酶1（DPP-1）抑制剂XH-S004在全球（不包括中国境内及港澳地 区）范围的开发、生产及商业化权利。复星医药将保留XH-S004在中国境内及中国港澳地区的开发、生 产及商业化权利。截至目前，全球范围内尚无与XH-S004采用同一分子机制的小分子口服抑制剂获批上 市。 XH-S004为复星医药拥有自主知识产权的小分子口服DPP-1抑制剂，其通过抑制DPP-1及其激活的中性 粒细胞丝氨酸蛋白酶降低炎症反应，从而阻断感染恶性循环及由此导致的气道结构损伤；截至目前， XH-S004用于治疗非囊性纤维化支气管扩张症于中国境内处于II期临床试验阶段、用于治疗慢性阻塞性 肺疾病（COPD）于中国境内处于Ib期临床试验阶段。 复星医药董事长陈玉卿表示，XH-S004是复星医药拥有自主知识产权的治疗呼吸系统疾病的创新药物， 其独特的机制和临床价值得到了合 ...